Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1–Induced OCT4/Nanog Pathway

2022 ◽  
pp. ji2001453
Author(s):  
Wenting Li ◽  
Xiaoqiong Duan ◽  
Chuanlong Zhu ◽  
Xiao Liu ◽  
Andre J. Jeyarajan ◽  
...  
Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1115
Author(s):  
Ismail Che Noh ◽  
Imran Ahmad ◽  
Siti Suraiya ◽  
Nur Fadhlina Musa ◽  
Asma Abdullah Nurul ◽  
...  

Cytokines play an important role in modulating inflammation during viral infection, including hepatitis C virus (HCV) infection. Genetic polymorphisms of cytokines can alter the immune response against this infection. The objective of this study was to investigate the possible association between chronic hepatitis C virus infection susceptibility and cytokine gene polymorphism for interleukin-10 (IL-10) rs1800896 and rs1800871, interleukin 6 (IL-6) rs1800795, TNF-α rs1800629, and TGF-β1 rs1800471 in Malay male drug abusers. The study was conducted on 76 HCV-positive (HP) male drug abusers and 40 controls (HCV-negative male drug abusers). We found that there were significant differences in the frequencies of genotype for IL-10 rs1800871 (p = 0.0386) and at the allelic level for IL-10 rs1800896 A versus G allele (p = 0.0142) between the HP group and the control group. However, there were no significant differences in gene polymorphism in interleukin 6 rs1800795, TNF-α rs1800629 and TGF-β1 rs1800471. These findings suggest significant associations between gene polymorphism for IL-10 rs1800871, IL-10 rs1800896 (at the allelic level) and susceptibility to HCV infection among Malay male drug abusers.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Kazuhiro Murai ◽  
Hayato Hikita ◽  
Yugo Kai ◽  
Yasuteru Kondo ◽  
Makoto Fukuoka ◽  
...  

2004 ◽  
Vol 41 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Angelo Alves de Mattos ◽  
Eliana Buksztejn Gomes ◽  
Cristiane Valle Tovo ◽  
Cláudio Osmar Pereira Alexandre ◽  
José Oscar dos Reis Remião

BACKGROUND: Considering the immunosuppression of patients with chronic liver disease, their response to vaccination is discussed in literature. AIMS: To evaluate the response of hepatitis B vaccine in patients with chronic hepatitis C virus infection. METHODS: This is a prospective study in which 85 patients with chronic hepatitis C virus infection (46.8 ± 9.4 years, 44.7% males) and 46 healthy adults (36.7 ± 11.1 years; 39.1% males) were evaluated. Confirmation of hepatitis C virus was obtained by the technique of polymerase chain reaction. Viral load was determined by the branched DNA method in 74 patients, and genotype was determined by sequencing in 73 patients. All patients and healthy adults received three doses of Engerix B® vaccine IM (at 0, 30 and 180 days). Serological responses to the vaccine were divided into three categories: seroprotection, when anti-HBs was >100 mUI/mL; seroconversion, when anti-HBs was 10-99 mUI/mL, and non-reagent, when anti-HBs was <10 mUI/mL. RESULTS: The response of hepatitis B vaccine as determined 1 month following dose 3 was seroprotection in 37.7%, seroconversion in 17.6% and non-reagent in 44.7% among patients and 84.8%, 13.0%, 2.2%, respectively in healthy adults. The number of non-reagent responses was significantly higher among those patients with chronic liver disease. Sixty-five patients with chronic hepatitis were compared to 20 compensated cirrhotic patients in concern to the response to vaccine, but no difference was found. The response to vaccine in patients with genotypes 2 or 3 (n = 40) was better than in those with genotype 1 (n = 33). Response was not related to serum HCV-RNA concentration. CONCLUSION: The number of non-responders was higher in patients with chronic hepatitis C virus infection, irrespective of histological status and viral load. It is suggested that such patients should receive a double dose of vaccine, particularly the ones with genotype 1.


2007 ◽  
Vol 28 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Robyn R. M. Gershon ◽  
Martin Sherman ◽  
Clifford Mitchell ◽  
David Vlahov ◽  
Melissa J. Erwin ◽  
...  

Objective.To determine the prevalence and risk factors for bloodborne exposure and infection in correctional healthcare workers (CHCWs).Design.Cross-sectional risk assessment study with a confidential questionnaire and serological testing performed during 1999-2000.Setting.Correctional systems in 3 states.Results.Among 310 participating CHCWs, the rate of percutaneous injury (PI) was 32 Pis per 100 person-years overall and 42 Pis per 100 person-years for CHCWs with clinical job duties. Underreporting was common, with only 25 (49%) of 51 Pis formally reported to the administration. Independent risk factors for experiencing PI included being age 45 or older (adjusted odds ratio [aOR], 2.41 (95% confidence interval (CI), 1.31-4.46]) and having job duties that involved needle contact (aOR, 3.70 [95% CI, 1.28-10.63]) or blood contact (aOR, 5.05 [95% CI, 1.45-17.54]). Overall, 222 CHCWs (72%) reported having received a primary hepatitis В vaccination series; of these, 150 (68%) tested positive for anti-hepatitis B surface antigen, with negative results significantly associated with receipt of last dose more than 5 years previously. Serologic markers of hepatitis В virus infection were identified in 31 individuals (10%), and the prevalence of hepatitis B virus infection was 2% (n = 7). The high hepatitis B vaccination rate limited the ability to identify risk factors for infection, but hepatitis C virus infection correlated with community risk factors only.Conclusion.Although the wide coverage with hepatitis B vaccination and the decreasing rate of hepatitis C virus infection in the general population are encouraging, the high rate of exposure in CHCWs and the lack of exposure documentation are concerns. Continued efforts to develop interventions to reduce exposures and encourage reporting should be implemented and evaluated in correctional healthcare settings. These interventions should address infection control barriers unique to the correctional setting.


1991 ◽  
Vol 163 (2) ◽  
pp. 400-402 ◽  
Author(s):  
G. Fattovich ◽  
A. Tagger ◽  
L. Brollo ◽  
G. Giustina ◽  
P. Pontisso ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document